share_log

Seelos Therapeutics | 10-K/A: Annual report (Amendment)

SEC announcement ·  Apr 29 08:33
Summary by Moomoo AI
Seelos Therapeutics, Inc. (Seelos), a biopharmaceutical company, has filed an amendment to its annual report for the fiscal year ended December 31, 2023. The amendment was submitted to include information required in Part III of Form 10-K, which was previously omitted from the original filing. This amendment restates Part III in its entirety and amends Part IV to include updated certifications by the company's principal executive officer and principal financial officer as required under the Sarbanes-Oxley Act of 2002. The amendment does not include any financial statements or alter any financial disclosures, nor does it reflect any changes to previously reported financial results. Seelos' shares are registered under Section 12(b) of the Securities Exchange Act of 1934 and are traded on The...Show More
Seelos Therapeutics, Inc. (Seelos), a biopharmaceutical company, has filed an amendment to its annual report for the fiscal year ended December 31, 2023. The amendment was submitted to include information required in Part III of Form 10-K, which was previously omitted from the original filing. This amendment restates Part III in its entirety and amends Part IV to include updated certifications by the company's principal executive officer and principal financial officer as required under the Sarbanes-Oxley Act of 2002. The amendment does not include any financial statements or alter any financial disclosures, nor does it reflect any changes to previously reported financial results. Seelos' shares are registered under Section 12(b) of the Securities Exchange Act of 1934 and are traded on The Nasdaq Stock Market LLC under the symbol SEEL. As of April 26, 2024, Seelos had 16,609,128 shares of common stock outstanding. The company's market value of voting stock held by non-affiliates was approximately $144.9 million as of the last business day of the most recently completed second fiscal quarter. The amendment also provides detailed information about the company's directors and executive officers, including their ages, positions, and terms of office. The company's corporate governance practices, including its Code of Ethics and Audit Committee operations, are outlined as well. Seelos has adopted a policy for the pre-approval of services provided by its independent auditors, ensuring that all such services are reviewed and approved in advance by the Audit Committee.

This announcement is a separate document:

Doc 1

Doc 2

Doc 3

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more